NASDAQ:KRTX

Karuna Therapeutics Stock Forecast, Price & News

$112.60
-4.69 (-4.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$112.07
Now: $112.60
$118.03
50-Day Range
$111.05
MA: $118.72
$124.96
52-Week Range
$69.58
Now: $112.60
$146.97
Volume185,345 shs
Average Volume206,767 shs
Market Capitalization$3.04 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Karuna Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KRTX
CUSIPN/A
CIKN/A
Phone857-449-2244
Employees63
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$16.65 per share

Profitability

Net Income$-43,960,000.00

Miscellaneous

Market Cap$3.04 billion
Next Earnings Date5/6/2021 (Estimated)
OptionableNot Optionable

Headlines

Karuna Therapeutics (NASDAQ:KRTX) Shares Gap Down to $119.94
April 9, 2021 |  americanbankingnews.com
KRTX Feb 2021 155.000 call
February 12, 2021 |  au.finance.yahoo.com
KRTX Mar 2021 55.000 put
February 12, 2021 |  au.finance.yahoo.com
KRTX Mar 2021 100.000 put
February 11, 2021 |  au.finance.yahoo.com
Insider Sells Karuna Therapeutics Stock
February 10, 2021 |  finance.yahoo.com
KRTX Feb 2021 100.000 put
January 31, 2021 |  au.finance.yahoo.com
Is KRTX A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
See More Headlines

MarketRank

Overall MarketRank

1.81 out of 5 stars

Medical Sector

142nd out of 2,024 stocks

Pharmaceutical Preparations Industry

60th out of 772 stocks

Analyst Opinion: 4.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$112.60
-4.69 (-4.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for KRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Karuna Therapeutics (NASDAQ:KRTX) Frequently Asked Questions

Is Karuna Therapeutics a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Karuna Therapeutics stock.
View analyst ratings for Karuna Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Karuna Therapeutics?

Wall Street analysts have given Karuna Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Karuna Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Karuna Therapeutics' next earnings date?

Karuna Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021.
View our earnings forecast for Karuna Therapeutics
.

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) announced its quarterly earnings results on Thursday, February, 25th. The company reported ($0.89) EPS for the quarter, meeting analysts' consensus estimates of ($0.89).
View Karuna Therapeutics' earnings history
.

How has Karuna Therapeutics' stock price been impacted by COVID-19?

Karuna Therapeutics' stock was trading at $78.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, KRTX shares have increased by 42.9% and is now trading at $112.60.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for KRTX?

11 equities research analysts have issued 12 month target prices for Karuna Therapeutics' stock. Their forecasts range from $126.00 to $167.00. On average, they anticipate Karuna Therapeutics' stock price to reach $144.70 in the next twelve months. This suggests a possible upside of 28.5% from the stock's current price.
View analysts' price targets for Karuna Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Karuna Therapeutics' key executives?

Karuna Therapeutics' management team includes the following people:
  • Dr. Steven M. Paul M.D., CEO, Pres & Chairman (Age 70, Pay $893.65k)
  • Dr. Andrew Craig Miller, Co-Founder & COO (Age 39, Pay $748.82k)
  • Dr. Troy A. Ignelzi, CFO & Sec. (Age 53, Pay $729.75k)
  • Mr. Jason Parker Brown, VP of Corp. Fin.
  • Ms. Mia Kelley J.D., VP of Legal Affairs
  • Ms. Sharon Sawchak R.N., VP of Clinical Operations & Compliance
  • Ms. Stephanie Moore, VP of HR
  • Dr. Alan Breier, Chair of Scientific Advisory Board & Chief Clinical Advisor
  • Dr. Stephen K. Brannan, Chief Medical Officer (Age 64)
  • Dr. James E. Audia Ph.D., Head of Medicinal Chemistry & Sr. Adviser (Age 64)

Who are some of Karuna Therapeutics' key competitors?

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and The Walt Disney (DIS).

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an initial public offering on Friday, June 28th 2019. The company issued 4,400,000 shares at $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Karuna Therapeutics' stock symbol?

Karuna Therapeutics trades on the NASDAQ under the ticker symbol "KRTX."

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Pacer Advisors Inc. (0.00%). Company insiders that own Karuna Therapeutics stock include Andrew Craig Miller, Arch Venture Partners Ix, Llc, Atul Pande, Edmund Harrigan, Heather Preston, James Healy, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends for Karuna Therapeutics
.

Which major investors are selling Karuna Therapeutics stock?

KRTX stock was sold by a variety of institutional investors in the last quarter, including Pacer Advisors Inc.. Company insiders that have sold Karuna Therapeutics company stock in the last year include Andrew Craig Miller, Atul Pande, Edmund Harrigan, Puretech Health Llc, Stephen K Brannan, Steven M Paul, and Troy A Ignelzi.
View insider buying and selling activity for Karuna Therapeutics
or view top insider-selling stocks.

How do I buy shares of Karuna Therapeutics?

Shares of KRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Karuna Therapeutics' stock price today?

One share of KRTX stock can currently be purchased for approximately $112.60.

How much money does Karuna Therapeutics make?

Karuna Therapeutics has a market capitalization of $3.04 billion. The company earns $-43,960,000.00 in net income (profit) each year or ($3.68) on an earnings per share basis.

How many employees does Karuna Therapeutics have?

Karuna Therapeutics employs 63 workers across the globe.

What is Karuna Therapeutics' official website?

The official website for Karuna Therapeutics is karunatx.com.

Where are Karuna Therapeutics' headquarters?

Karuna Therapeutics is headquartered at 33 ARCH STREET SUITE 3110, BOSTON MA, 02110.

How can I contact Karuna Therapeutics?

Karuna Therapeutics' mailing address is 33 ARCH STREET SUITE 3110, BOSTON MA, 02110. The company can be reached via phone at 857-449-2244 or via email at [email protected]


This page was last updated on 4/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.